Table 2.
Clinical and pathological characteristics of the TAm-Seq study cohort
| n | 189 |
|---|---|
| Age (years) | |
| Median | 63 |
| IQR | 58–67.6 |
| PSA ng/ml | |
| Median | 7.5 |
| IQR | 5.3–12.95 |
| cT | |
| 1 | 105 (55.6%) |
| 2 | 63 (33.3%) |
| 3 | 21 (11.1%) |
| Biopsy ISUP Grade Group | |
| 1 | 33 (17.5%) |
| 2 | 61 (32.3%) |
| 3 | 29 (15.3%) |
| 4 | 35 (18.5%) |
| 5 | 31 (16.4%) |
| pT | |
| 2 | 88 (46.6%) |
| 3a | 60 (31.7%) |
| 3b | 41 (21.7%) |
| Prostatectomy ISUP Grade Group | |
| 1 | 10 (5.3%) |
| 2 | 63 (33.3%) |
| 3 | 61 (32.3%) |
| 4 | 11 (5.8%) |
| 5 | 44 (23.3%) |
| Tumour volume (cc) | |
| Median | 3.35 |
| IQR | 1.5–7.37 |
| Biochemical recurrence | |
| No | 90 (47.6%) |
| Yes | 99 (52.4%) |
| Metastases | |
| No | 117 (61.9%) |
| Yes | 49 (35.9%) |
| Not reported | 23 (12.2%) |